News Brief
Bharat Biotech’s COVAXIN, India’s first indigenous vaccine against coronavirus. (Swarajya Magazine)
The final phase 3 analysis of Covaxin, the Covid-19 jab developed by Bharat Biotech, has shown the efficacy of 78 per cent in preventing symptomatic coronavirus caused disease, a report said.
Officials familiar with the development said that the Hyderabad-based vaccine maker is likely to announce the results in June.
As per previous reports, while the first interim efficacy analysis had shown the efficacy of nearly 81 per cent, the second interim analysis results showed it to be about 78 per cent.
Dr Sanjay Rai, professor, community medicine department, All India Institute of Medical Sciences (AIIMS), Delhi told Hindustan Times: “The final analysis was done at 130 confirmed case and it was found to be 78 per cent.”
“The interim analysis may be over, the analysed data needs to be peer-reviewed and published in a medical journal now,” added Dr Rai who is also the principal investigator of the study site at AIIMS.
While confirming the news about the vaccine, another official in the central government said: “We have been made to understand that the interim analysis results for Covaxin phase 3 trials are almost done and they are in the process of publishing the data.”
This analysis comes at a time when Bharat Biotech has applied for emergency use listing (EUL) from the World Health Organization (WHO) and the company is expecting a nod from the UN health agency by July-September.
The researchers have analysed Covaxin’s efficacy at several, pre-set interval—known as endpoints.
The first interim analysis is based on 43 cases, of which 36 cases of COVID-19 were observed in the placebo group versus 7 cases observed in the Covaxin group, resulting in a point estimate of vaccine efficacy of 80.6 per cent.
The results were released in March 2021.
The second interim analysis result, released in April, was based on accruing more than 87 symptomatic Covid-19 cases.
It showed that the efficacy of the vaccine against the coronavirus caused disease was 100 per cent and a reduction of hospitalization numbers was also noted.
Even though Bharat Biotech has not yet revealed any details about the final analysis, in April the company said that the safety and efficacy details will be available by June.
The vaccine maker also stated that the final results will be submitted to a peer-reviewed publication.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest